ECM

TenNor Therapeutics (丹诺医药) IPO: Rich valuation for an antibacterial deal

14 May 2026 By Ke Yan, CFA
← All Research ReportsMore ECM coverage →

Abstract: TenNor Therapeutics, a China-based biotech, launched its IPO to raise at least USD 80 million via a Hong Kong listing. In this note, we look at the deal terms and provide our valuation thoughts for the company. We summarize the dynamics for the deal and would not participate.

Interested in the full report? Get in touch with our team.